[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"duodenal-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:duodenal-cancer":37},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,100,140],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":77,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":99},"100210159","integrated-cancer-repository-for-cancer-research-100210159",false,"NCT02012699","Integrated Cancer Repository for Cancer Research","iCaRe2","Inclusion Criteria\n\n* Diagnosis\u002Fhistory of cancer\n* Risk for developing cancer or suspicious clinical findings\n* No history of cancer (normal control registry)\n* Able to provide informed consent\n* 19 years of age or older\n* English or Spanish speaking individuals\n\nExclusion Criteria\n\n* Unable to provide informed consent because of cognitive impairment\n* Non-English or non-Spanish speaking individuals",true,"ALL","19 Years","110 Years",{"count":21,"type":22},999999,"ESTIMATED","80 Years","OBSERVATIONAL","The iCaRe2 is a multi-institutional resource created and maintained by the Fred \\& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, high-risk individuals, and normal controls. The distinct characteristic of the iCaRe2 is its geographical coverage, with a significant percentage of small and rural hospitals and cancer centers. The iCaRe2 advances comprehensive studies of risk factors of cancer development and progression and enables the design of novel strategies for prevention, screening, early detection and personalized treatment of cancer. Centers with expertise in cancer epidemiology, genetics, biology, early detection, and patient care can collaborate by using the iCaRe2 as a platform for cohort and population studies.",[27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76],"Pancreatic Cancer","Thyroid Cancer","Lung Cancer","Esophageal Cancer","Thymus Cancer","Colon Cancer","Rectal Cancer","Gastrointestinal Stromal Tumors","Anal Cancer","Bile Duct Cancer","Duodenal Cancer","Gallbladder Cancer","Gastric Cancer","Liver Cancer","Small Intestine Cancer","Peritoneal Surface Malignancies","Familial Adenomatous Polyposis","Lynch Syndrome","Bladder Cancer","Kidney Cancer","Penile Cancer","Prostate Cancer","Testicular Cancer","Ureter Cancer","Urethral Cancer","Hypopharyngeal Cancer","Laryngeal Cancer","Lip Cancer","Oral Cavity Cancer","Nasopharyngeal Cancer","Oropharyngeal Cancer","Paranasal Sinus Cancer","Nasal Cavity Cancer","Salivary Gland Cancer","Skin Cancer","Central Nervous System Tumor","Central Nervous System Cancer","Mesothelioma","Breast Cancer","Leukemia","Melanoma","Sarcoma","Unknown Primary Tumor","Multiple Myeloma","Ovarian Cancer","Endometrial Cancer","Vaginal Cancer","Neuroendocrine Tumors","Plasma Cell Dyscrasia","Healthy Control",[27,28,78,79,80,81,82,83,84,85,65,86,75,76],"Esophageal cancer","Thymus cancer","Pancreatic tumor","Esophageal tumor","Thymus tumor","Thyroid Tumor","Thyroid Nodule","Lung Tumor","Neuroendocrine tumor","RECRUITING","2026-06-25",{"date":90,"type":91},"2026-06-29","ACTUAL",{"date":93,"type":91},"2013-11-01",{"date":95,"type":22},"2099-12",{"name":97,"class":98},"University of Nebraska","OTHER",42,{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":106,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":17,"minAge":108,"maxAge":109,"enrollmentInfo":110,"targetDuration":4,"studyType":112,"phases":113,"briefSummary":115,"conditions":116,"keywords":121,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":139},"100604900","phase-3-tissue-adhesive-glue-modified-cyanoacrylate-glubran-2-in-soft-pancreas-100604900","NCT07155525","Tissue Adhesive Glue Modified Cyanoacrylate (Glubran® 2) in Soft Pancreas","Pancreaticojejunostomy With or Without Modified N-butyl-2-cyanoacrylate Following Pancreaticoduodenectomy in Soft Pancreas: Randomized Controlled Trial","NBCA-MS","Inclusion Criteria:\n\n* Patients scheduled for elective pancreaticoduodenectomy for malignant lesions.\n* Intraoperative confirmation of soft pancreatic texture (by surgeon palpation; friable, non-fibrotic pancreas).\n* Age 18-75 years .\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-2.\n* Adequate organ function defined as:\n\nHemoglobin ≥ 9.0 g\u002FdL Absolute neutrophil count ≥ 1,500\u002FμL Platelet count ≥ 100,000\u002FμL Total bilirubin ≤ 3 times upper limit of normal Alanine transaminase (ALT) \u002FAlanine transaminase (ALT)( ≤ 5 times upper limit of normal Serum creatinine ≤ 1.5 times upper limit of normal\n\n* Informed consent provided.\n* Willingness to comply with study procedures and follow-up requirements.\n\nExclusion Criteria:\n\n* Hard pancreatic texture (intraoperative surgeon assessment).\n* Emergency surgery.\n* Previous pancreatic surgery or pancreatic anastomosis.\n* Intraoperative identification of unresectable disease\n* Known allergy to cyanoacrylate or components.\n* Pregnancy or lactation.\n* Active infection or sepsis.\n* Inability to comply with follow-up.","18 Years","75 Years",{"count":111,"type":22},194,"INTERVENTIONAL",[114],"PHASE3","This is a single-center, randomized controlled trial comparing the efficacy of pancreaticojejunostomy with modified N-butyl-2-cyanoacrylate(Glubran® 2) versus standard pancreaticojejunostomy without cyanoacrylate in preventing postoperative pancreatic fistula (POPF) in patients undergoing pancreaticoduodenectomy with soft pancreatic texture. The primary endpoint is the incidence of postoperative pancreatic fistula at 30 days post-surgery, as defined by the International Study Group on Pancreatic Fistula (ISGPF) criteria.Secondary outcomes include surgical complications and length of hospital stay. The study will enroll approximately 194 patients at a single center.",[27,117,37,118,119,120,36],"Periampullary Cancer","Cholangiocarcinoma","Pancreatic Ductal Adenocarcinoma","Pancreatic Head Mass",[122,123,124,125,126,127,128,129],"Pancreaticoduodenectomy","Pancreaticojejunostomy","Postoperative Pancreatic Fistula","Soft Pancreas","N-Butyl-2-Cyanoacrylate","Whipple procedure","Tissue adhesive","POPF prevention","2025-09-14",{"date":132,"type":91},"2025-09-18",{"date":134,"type":91},"2025-09-15",{"date":136,"type":22},"2028-11-15",{"name":138,"class":98},"Minia University",1,{"id":141,"slug":142,"hasResults":11,"nctId":143,"briefTitle":144,"officialTitle":145,"acronym":146,"eligibilityCriteria":147,"healthyVolunteers":11,"sex":17,"minAge":108,"maxAge":4,"enrollmentInfo":148,"targetDuration":4,"studyType":112,"phases":150,"briefSummary":152,"conditions":153,"keywords":4,"overallStatus":156,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":139},"100547911","modulated-mid-frequency-whole-body-electromyostimulation-and-nutritional-therapy-in-gastrointestinal-cancer-patients-100547911","NCT06414122","Modulated Mid-frequency Whole-body Electromyostimulation and Nutritional Therapy in Gastrointestinal Cancer Patients","The Efficacy of Modulated Mid-frequency (Whole-body Electromyostimulation) and Nutritional Therapy in Patients With Solid Tumors of the Gastrointestinal Tract (Excluding Liver and Pancreatic Carcinomas)","MOMENT","Inclusion Criteria:\n\n* Patients with oesophageal, gastric, duodenal, colon or rectal cancer following surgery without further therapy and with neoadjuvant and adjuvant therapy\n* medical clearance for exercise training\n* written declaration of consent from the study participant\n\nExclusion Criteria:\n\n* Participation in another study on the topic of exercise or nutrition\n* Electronic implants such as pacemakers, pumps, and coronary stents\n* Cardiac arrhythmia\n* Implants in the area of application (e.g. breast implants)\n* Pregnancy\n* Epilepsy\n* Wounds and open skin diseases in the area of application of the electrodes\n* Unhealed operations or bone fractures\n* Acute inflammatory diseases (e.g. inflammation of the intervertebral discs, bones, vessels, or soft tissue)\n* Directly after herniated discs or other instabilities such as large abdominal wall hernias\n* Blood clots (thromboses)\n* Bone diseases with high-grade osteoporosis\n* Increased risk of haemorrhage\n* Fever and illnesses that can be aggravated by physical exertion\n* Untreated high blood pressure\n* Blindness\n* Continuous parenteral nutrition\n* Metal and electronic parts in the body (e.g. prostheses, metal vascular clips, hearing aids\u002Finner ear\u002Fcochlear implants, magnetic dental prostheses, pacemakers, contraceptives)",{"count":149,"type":22},88,[151],"NA","The purpose of this study is to assess the efficacy of modulated mid-frequency whole-body electromyostimulation (WB-EMS) combined with nutritional therapy in patients with gastrointestinal cancer.",[154,39,37,155],"Oesophageal Cancer","Colorectal Cancer","NOT_YET_RECRUITING","2025-03-14",{"date":159,"type":91},"2025-03-19",{"date":161,"type":22},"2025-06",{"date":163,"type":22},"2026-09",{"name":165,"class":98},"University of Cologne"]